GeoffreyRaymondOxnardMD

Oncology • Boston, MA

Hematologic Oncology

Instructor in Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Oxnard is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Oxnard's full profile

Already have an account?

Office
450 Brookline Ave
Dana-Farber Cancer Institute, D1234
Boston, MA 02215
Phone(617) 632-6049
Fax(617) 632-5786
Is this information wrong?

Education & Training

Memorial Sloan-Kettering Cancer CenterFellowship, Hematology/Oncology, 2008 - 2011
Massachusetts General HospitalResidency, Internal Medicine, 2005 - 2008
University of Chicago Pritzker School of MedicineClass of 2005

Certifications & Licensure

NY State Medical License 2008 - Present
MA State Medical License 2007 - 2021
American Board of Internal Medicine Medical Oncology

Clinical Trials

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer Start of enrollment: 2016 Jun 01Geoffrey R Oxnard, MD
A Randomized Open-Label Phase II Trial of Pemetrexed and a Platinum (Carboplatin or Cisplatin) With or Without Erlotinib in Patients With Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations and Acquired Resistance to Start of enrollment: 2013 Aug 01Horn, L.,Riely, G.J.,Govindan, R.,Oxnard, G.R.
A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity Start of enrollment: 2013 May 01Heist, R.S.,Costa, D.B.,Oxnard, G.R.
INHERIT EGFR - Studying Germline EGFR Mutations Start of enrollment: 2012 Dec 01Oxnard, G.,Wiesner, G.
Afatinib With CT and RT for EGFR-Mutant NSCLC Start of enrollment: 2012 Apr 01Oxnard, G.,Sequist, L.V.
Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance Geoffrey R Oxnard, MD
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib Geoffrey R Oxnard, MD and Myung-Ju Ahn, MD

Publications & Presentations

PubMed

Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib
Ezra Y. Rosen, Melissa Lynne Johnson, Sarah E. Clifford, Romel Somwar, Jennifer Kherani, Jieun Son, Arrien A. Bertram, Monika A. Davare, Eric Gladstone, Elena Ivanova,...> ;Clinical Cancer Research. 2021 Jan 1
Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations
Atsuko Ogino, Jihyun Choi, Mika Lin, Margaret K. Wilkens, Antonio Calles, Man Xu, Anika E. Adeni, Emily S. Chambers, Marzia Capelletti, Mohit Butaney, Nathanael S. Gra...> ;Molecular Oncology. 2021 Jan 1
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice.
Charu Aggarwal, C. Rolfo, Geoffrey R. Oxnard, Jhanelle E. Gray, Lynette M. Sholl, David R. Gandara> ;Nature Reviews Clinical Oncology. 2021 Jan 1
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
Erin M. Bertino, Ryan D. Gentzler, Sarah E. Clifford, Jill M. Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, Chris...> ;Clinical Cancer Research. 2020 Dec 29
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Michael L. Cheng, Eirini Pectasides, Glenn J. Hanna, Heather A. Parsons, Atish D. Choudhury, Geoffrey R. Oxnard> ;CA: A Cancer Journal for Clinicians. 2020 Nov 9
Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.
Firas S. Ahmed, Laurent Dercle, Gregory V. Goldmacher, Hao Yang, Dana E. Connors, Ying Tang, Sanja Karovic, Binsheng Zhao, Richard D. Carvajal, Caroline Robert, Michae...> ;European Radiology. 2020 Sep 30
Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.
Michael L. Maitland, J. Wilkerson, Sanja Karovic, Binsheng Zhao, Jessica Flynn, Mengxi Zhou, Patrick Hilden, Firas S. Ahmed, Laurent Dercle, Chaya S. Moskowitz, Ying T...> ;Clinical Cancer Research. 2020 Sep 28
Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis.
Yi Lee, Evan W. Clark, Marina S.D. Milan, Christine Champagne, Kesi S. Michael, Mark M. Awad, David A. Barbie, Michael L. Cheng, Kenneth L. Kehl, J. Paul Marcoux, Mich...> ;2020 Sep 21
State of the Science and Future Directions for Liquid Biopsies in Drug Development.
Preeti Narayan, Soma Ghosh, Reena Philip, J. Carl Barrett, Robert McCormack, Justin I. Odegaard, Geoffrey R. Oxnard, Laurel J. Pracht, P. Mickey Williams, Gary J. Kell...> ;Oncologist. 2020 Sep 1
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa Lynne Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin B...> ;The New England Journal of Medicine. 2020 Aug 26
Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy.
Lynette M. Sholl, Geoffrey R. Oxnard, Cloud P. Paweletz> ;Cancer Research. 2020 Aug 15
Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Alissa J. Cooper, Yoshihisa Kobayashi, Dewey Kim, Sarah E. Clifford, Sasha Kravets, Suzanne E. Dahlberg, Emily S. Chambers, Jiaqi Li, Deepa Rangachari, Tom Nguyen, Dan...> ;Clinical Cancer Research. 2020 Aug 1
Response to W.C. Taylor, and C. Fiala and E.P. Diamandis.
Minetta C. Liu, Geoffrey R. Oxnard, Eric A. Klein, Charles Swanton, Michael V. Seiden> ;Annals of Oncology. 2020 Jun 19
3 citations
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
Min Liu, G.R. Oxnard, E.A. Klein, C. Swanton, M.V. Seiden, Minetta C. Liu, Geoffrey R. Oxnard, Eric A. Klein, David Smith, Donald A. Richards, Timothy J. Yeatman, Alle...> ;Annals of Oncology. 2020 Jun 1
Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Susan E Jorge, Antonio R Lucena-Araujo, Hiroyuki Yasuda, Zofia Piotrowska, Geoffrey R Oxnard, Deepa Rangachari, Mark S Huberman, Lecia V Sequist, Susumu S Kobayashi, D...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 May 1
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Geoffrey R. Oxnard, J.C.-H. Yang, Helena Alexandra Yu, Sang We Kim, Hideo Saka, Leora Horn, Koichi Goto, Yuichiro Ohe, Helen Mann, Kenneth S. Thress, Melanie M. Frigau...> ;Annals of Oncology. 2020 Apr 1
Blood-Based Disease Assessment in SCLC: A Perpetual Proof of Concept or a Clinically Important Tool?
Sands, J. M., Milan, M. S., Oxnard, G. R.> ;Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 Mar 5
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: i...
Lecia V. Sequist, Ji Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena A. Yu, Sang We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu Chou Su, Dariusz M. Kowalski, Sergey O...> ;Lancet Oncology. 2020 Mar 1
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo, G., Bahcall, M., Spurr, L. F., Che, J., Ricciuti, B., Leonardi, G. C., Lo, Y., Li, Y. Y., Lamberti, G., Nguyen, T., Milan, M. S., Venkatraman, D., Umeton, R.,...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Feb 9
Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer
Elena Ivanova, Mari Kuraguchi, Man Xu, Andrew Portell, Luke J. Taus, Irmina Diala, Alshad S. Lalani, Jihyun Choi, Emily S. Chambers, Shuai Li, Shengwu Liu, Ting Chen, ...> ;Clinical Cancer Research. 2020 Feb 7
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon, B. J., Tan, L., Lin, J. J., Wong, S. Q., Hollizeck, S., Ebata, K., Tuch, B. B., Yoda, S., Gainor, J. F., Sequist, L. V., Oxnard, G. R., Gautschi, O., Drilon, ...> ;Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020 Jan 29
Circulating tumor DNA analysis in the era of precision oncology.
Rabih Said, N. Guibert, Geoffrey R. Oxnard, Apostolia Maria Tsimberidou> ;Oncotarget. 2020 Jan 14
Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
Sands, J. M., Nguyen, T., Shivdasani, P., Sacher, A. G., Cheng, M. L., Alden, R. S., Jänne, P. A., Kuo, F. C., Oxnard, G. R., Sholl, L. M.> ;Lung cancer (Amsterdam, Netherlands). 2019 Dec 20
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Leora Horn, Jennifer G. Whisenant, Heather A. Wakelee, Karen L. Reckamp, Huan Qiao, Ticiana A. Leal, Liping Du, Jennifer Hernandez, Vincent Huang, George R. Blumensche...> ;Journal of Thoracic Oncology. 2019 Nov 1
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in...
Rangachari, D., To, C., Shpilsky, J. E., VanderLaan, P. A., Kobayashi, S. S., Mushajiang, M., Lau, C. J., Paweletz, C. P., Oxnard, G. R., Jänne, P. A., Costa, D. B.> ;Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Aug 5
Join now to see all

Lectures

Prognostic significance of blood-based cancer detection in plasma cell-free DNA (cfDNA): Evaluating risk of overdiagnosis.
2019 ASCO Annual Meeting - 6/1/2019
SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung c...
2019 ASCO Annual Meeting - 6/1/2019
Genome-wide sequencing for early stage lung cancer detection from plasma cell-free DNA (cfDNA): The Circulating Cancer Genome Atlas (CCGA) study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Biopsies (Blood, Urine, Tumor): When to Do Them and What Do They Mean?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Authored Content

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020

Press Mentions

AstraZeneca Announces Winners and Recognizes Unsung Heroes of Oncology in 2020 Cancer Community (C2) AwardsOctober 22nd, 2020
Over 50 Types of Cancer Diagnosed with New Blood TestApril 6th, 2020
This New Blood Test Accurately Predicts 50 Types of CancerApril 2nd, 2020
Join now to see all